

PULMONARY HYPERTENSION BOLOGNA 2018

Horizon 2020 and beyond: New Classes of Drugs or New Treatment Strategies?

Royal Hotel Carlton - Bologna

Friday – 23RD of November

Timing	Session Title	Lecture Title
13:00 – 13:30		Registration
13:30 – 14:00		Introduction and presentation of the meeting objectives (N. Galiè)
14:00 – 16:00	NEW CLASSES OF PAH DRUGS ON THE HORIZON (Chairs: M. Humbert, N. Galiè)	Any suggestions from PH pathology? (P. Dorfmüller) Any Insights from PH Pathobiology? (M. Humbert) Any Insights from Genetics? (N. Morrell) The clinical development plan for a new class of drugs in PAH (G. Simonneau)
16:00 – 16:30	Coffee break	
16:30 – 18:30	NEW TREATMENT STRATEGIES ON THE HORIZON (Chairs: G. Simonneau, A. Torbicki)	Comparative evaluation of risk stratification strategies in PAH (A. Boucly) Results of low-risk oriented sequential combination therapy (F. Dardi) Double or triple initial combination therapy in PAH? (O. Sitbon) The horizon for the PAH treatment algorithm (N. Galiè)
18:30 – 18.45	Summary of the Day	N. Galiè

Saturday – 24TH of November

Timing	Session Title	Lecture Title
09:00 – 10:30	ANY NEWS FROM OTHER CLINICAL GROUPS? Chairs: (O. Sitbon, J.L.Vachier)	Pulmonary Hypertension in Children (M. Beghetti) Left heart disease (J.L. Vachier) Lung Disease (S.P. Gaine)
10:30 – 10:45	Coffee Break	
10:45 – 12:00	WHAT IS THE HORIZON FOR INTERVENTIONS? (D. Pacini, D.P. Jenkins)	Balloon Pulmonary Angioplasty in CTEPH (M. Palazzini) Pulmonary Endoarterectomy (D. P. Jenkins) Pulmonary Artery Ablation (A. Rothman)
12:00- 13:45	THE CLINICAL CASES Chairs: (A. Manes, A. Aldalaan)	Case # 1 – A PAH low-risk case (E. Zuffa) Case # 2 – A PAH intermediate-risk case (A. Rinaldi) Case # 3 – A PAH high-risk case (S. Orfanos) Case # 4 – CTEPH decision making (E. Gotti) Case # 5 – PH due to Congenital Heart Disease (H. Sakkijha) Case # 6 – PH due to connective tissue disease (H. Sabbour)
13.45-13:50	Summary of the Day & Conclusions	N. Galiè
13:50-14:45	Lunch	